Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566) disclosed a repurchase of 680,400 H shares on 4 February 2026. The company’s opening balance on 3 February 2026 showed 107,208,585 issued shares (excluding treasury shares) and 1,888,200 treasury shares, totaling 109,096,785 shares.

Following the repurchase, the number of issued shares (excluding treasury shares) decreased to 106,528,185, while treasury shares increased to 2,568,600. The total number of issued shares remained at 109,096,785. Repurchase prices ranged between HKD 9.81 and HKD 10.74, resulting in an aggregate consideration of approximately HKD 7.26 million.

According to the disclosure, there is a moratorium period extending to 6 March 2026, during which no new shares may be issued or released from treasury without prior approval. The update reflects the most recent changes in the company’s shareholding structure recorded as of 4 February 2026.